The b C protein of group B streptococci (GBS) elicits antibody that is protective against GBS challenge in animals and is considered to be a potential component of a GBS conjugate vaccine. We developed a quantitative enzyme-linked immunosorbent assay to measure b-specific serum immunoglobulin G (IgG) levels and used it to compare b-specific IgG in a group of mothers of neonates with invasive type Ib/b GBS disease and a group of mothers colonized with Ib/b strains whose neonates remained well. b-Specific IgG concentrations from these 2 groups were similar. To investigate differences in b-specific antibody in animals and humans, protein fragments were generated that corresponded to major regions within the b C protein. A single major region was predominantly recognized in human and rabbit serum samples. Thus, in contrast to immunized animals, no relationship was seen between levels of naturally acquired human b-specific IgG and protection from neonatal disease. This difference was not explained by a major difference in epitope specificity.
The b C protein of group B streptococci (GBS) elicits antibody that is protective against GBS challenge in animals and is considered to be a potential component of a GBS conjugate vaccine. We developed a quantitative enzyme-linked immunosorbent assay to measure b-specific serum immunoglobulin G (IgG) levels and used it to compare b-specific IgG in a group of mothers of neonates with invasive type Ib/b GBS disease and a group of mothers colonized with Ib/b strains whose neonates remained well. b-Specific IgG concentrations from these 2 groups were similar. To investigate differences in b-specific antibody in animals and humans, protein fragments were generated that corresponded to major regions within the b C protein. A single major region was predominantly recognized in human and rabbit serum samples. Thus, in contrast to immunized animals, no relationship was seen between levels of naturally acquired human b-specific IgG and protection from neonatal disease. This difference was not explained by a major difference in epitope specificity.
Group B streptococci (GBS; Streptococcus agalactiae ) are a leading cause of invasive disease in neonates, pregnant women, and immunocompromised adults. During the 1990s, the widespread use of intrapartum chemoprophylaxis resulted in a 65% decline in the number of early-onset neonatal GBS cases, but no decline has been seen among older neonates, infants, or nonpregnant adults [1] . Maternal immunization with GBS capsular polysaccharide-protein conjugate vaccines has the potential to decrease the disease burden even further. Studies of pregnant women and their infants have demonstrated that maternal antibody to the GBS capsular polysaccharide protects newborns from invasive GBS infection [2] and that efficient placental transport of vaccine-induced GBS antibodies occurs [3] . Recent attention has focused on the development of a conjugate vaccine that includes a GBS surface protein [4] . Such a vaccine has the potential to induce antibodies to additional protective epitopes while enhancing the immunogenicity of the polysaccharide component.
The b C protein is a 130-kD protein found on nearly all GBS strains of serotype Ib, as well as on some type Ia and II strains [5, 6] . In animals, vaccination with the b C protein elicits antibodies that are opsonic in vitro and protective in a lethal GBS sepsis model [4] . Furthermore, vaccination with the b C protein conjugated to the type III polysaccharide elicits antibodies in mice that are protective against lethal challenge with GBS strains that express either the type III capsule or the b C protein [4] . On the basis of these findings, the b C protein has been proposed as a component of a GBS conjugate vaccine intended for human use.
No work published to date has addressed the antibody response to the b C protein and its role in immunity to GBS disease in humans. Herein, we report the development of a quantitative ELISA to measure human b-specific serum IgG and to compare b-specific serum IgG levels in women whose babies developed early-onset type Ib GBS disease and in a group of control mothers whose babies remained healthy despite exposure to maternal type Ib colonization.
Materials and Methods
Bacterial strains and antiserum. Strain 7357B is a type Ib/b + / a 2 strain obtained from the collection of the Channing Laboratory (Boston) [4] . Additional GBS strains were isolated from the blood of neonates aged ,7 days or from vaginal and/or rectal cultures obtained, at admission for delivery, from maternal control subjects (see following paragraph) [7] . With use of hot HCl or trypsin extraction followed by double diffusion in agarose [5] human reference serum samples [8] , rabbit antiserum to the b C protein [4] , and 3E7, a monoclonal antibody specific for the b C protein [6] , have been described elsewhere.
Human serum. As part of an ongoing case-control study, serum samples were obtained from 5 women at admission for delivery of neonates who subsequently developed GBS sepsis due to a type Ib/ b C protein strain during the first 6 days of life. For each case, serum samples from 2 or 3 matched control subjects were studied. Control subjects were women delivered of neonates who remained healthy through the first 6 days of life; control subjects were matched with the corresponding case patient by maternal (1) ethnic origin, (2) age within a decade, and (3) colonization with a type Ib/b C protein strain. All case infants were born after a gestation of at least 36 weeks. Maternal serum samples were obtained at admission for delivery, separated by centrifugation, aliquoted, and stored at 280 C until testing was performed. Serum samples were obtained from healthy adult, nonpregnant laboratory volunteers and stored in the same manner. Written informed consent was obtained from patients and volunteers.
Purification of native b C protein.
Protein purification was adapted from methods published elsewhere [9] . Strain 7357B, a type Ib/b strain, was grown in Columbia broth (Difco Laboratories) that contained 50 g dextrose/L in a 20-L fermenter (LSL BioLafitte) for 24 h [10] . Bacterial cells were centrifuged at 10,000 g for 20 min at 4 C. The pellet from a 1.6-L culture was resuspended in 40 mL of 2% SDS and boiled, with stirring, for 1 h. The mixture was centrifuged at 10,000 g for 15 min at 4 C, and the resulting supernatant was used as the b C protein source. Ice-cold ethanol was added (2.5 vol), and the mixture was centrifuged at 10,000 g for 15 min. The pellet was resuspended in 300 mL of 10 mM Tris buffer (pH 8.0). Proteins were precipitated with the addition of 30 mL of 10% tricholoroacetic acid at room temperature. The precipitate was separated by centrifugation at 10,000 g for 15 min and resuspended in 20 mL of 10 mM Tris buffer (pH 8.0). The pH was adjusted to 8.0 with the addition of 10 N NaOH. The protein was reprecipitated with ice-cold ethanol (2.5 vol), and the mixture was centrifuged at 10,000 g for 15 min. The pellet was resuspended at 37 C in 140 mL loading buffer (0.1 M Tris, 0.5 mL NaCl, 10 mM EDTA, and 2% SDS) and again centrifuged for 15 min at 10,000 g. Proteins in the supernatant were separated on a gel filtration column (Sephacryl S300HR; Amersham Pharmacia Biotech) equilibrated with equilibration buffer (0.1 M Tris, 0.5 M NaCl, 10 mM EDTA, and 0.1% SDS) at 37%. Fractions were analyzed by Coomassie-stained SDS-PAGE and Western blot that used b-specific antiserum or monoclonal antibody 3E7. Positive fractions were pooled and subjected to an additional ethanol precipitation step, as above, to reduce the SDS content. The mixture was centrifuged at 10,000 g at 4 C for 30 min, and the resulting pellet was resuspended in 0.1 M carbonate buffer (pH 9.8). Protein purity was analyzed by Coomassiestained SDS-PAGE and Western blot that used b-specific antiserum or monoclonal antibody 3E7. Protein content was determined (BCA Protein Assay Kit; Pierce). SDS content was analyzed according to the method of Arand et al. [11] .
ELISA measurement of b-specific antibodies in human serum. Quantitative measurement of b-specific antibodies in human serum samples was performed by an ELISA adapted from methods described elsewhere [12] . Serial 2-fold dilutions of serum samples in incubation buffer (10 mM PBS with 0.05% Brij [Sigma Diagnostics], 5% newborn calf serum [Whittaker Bioproducts], and 0.02% azide), starting at 1:100, were added to duplicate wells of microtiter plates (Nunc-immuno plates; American Bioanalytical) coated with 1.25 mg/mL of purified b protein in 0.1 M carbonate buffer (pH 9.8). Absorbance at 405 nm (A 405 ) was determined after incubation with alkaline phosphatase-labeled goat anti-human IgG or goat antihuman IgA (Biosource International) diluted 1:3000 in incubation buffer. Optimal concentrations of coating antigen and secondary antibody were determined by checkerboard ELISA.
Levels of b-specific IgG in serum samples obtained from 19 laboratory volunteers were measured to compare optical density measurements from the b-specific IgG ELISA to a standard curve. The standard curve was generated by an ELISA that used unlabeled goat F(ab) 2 anti-human IgG (Accurate Chemical & Scientific), diluted to 1.25 mg/mL in 0.1 M carbonate buffer (pH 9.8), to coat plates and serial 2-fold dilutions of unlabeled affinity-purified human IgG (Accurate Chemical & Scientific Corp.) in incubation buffer starting at 0.1 mg/mL. The concentrations of b-specific IgG in serum samples from laboratory volunteers was 0.26-7.03 mg/mL. The serum sample that contained a concentration of 7.03 mg/mL was designated as the b human reference serum, and a serum sample that contained a concentration of 1.85 mg/mL was designated the internal control serum. For case and control serum samples, b-specific IgG was measured by comparison of the A 405 of the test sample to a standard curve generated from an ELISA with the b human reference serum. The internal control serum was included on each ELISA plate, to assess interassay variability. For all case and control serum samples, antibody measurements were performed on 2 or, if the antibody level was .1.0 mg/mL, 3 different days; the final antibody concentration was determined to be the mean of the values obtained from the separate experiments.
Inhibition ELISAs were performed by mixing selected serum samples at a single concentration with concentrations of one of the following inhibiting antigens: purified b C protein, affinitypurified human myeloma IgA (ICN Pharmaceuticals), or human serum albumin (Sigma) in concentrations of 0.0017-105 mg/mL. In the inhibition ELISAs, a serum concentration that corresponded to an A 405 of 1.0 (i.e., the middle of the linear portion of the uninhibited ELISA curve) was used. Percent inhibition was calculated as follows: [(A 405 of uninhibited control ÿ A 405 of test sampleÞ= A 405 of uninhibited control £ 100.
Removal of IgA1 from human serum. IgA1 was removed from the b human reference serum by use of a jacalin column. Immobilized jacalin (Pierce Chemical) was packed on a 5-mL column, according to the manufacturer's instructions. The column was washed with 5-column volumes of binding buffer (0.15 M NaCl and 0.1 M NaH 2 PO 4 ). Two milliliters of human serum diluted 1:20 with binding buffer was applied to the column, 5 additional column volumes of wash buffer were applied, and the effluent (serum) was used in ELISA studies that used goat anti-human IgA or anti-human IgG.
Opsonophagocytosis studies. The functional capacity of human antibodies to the b C protein was assessed by an opsonophagocytic assay that measured the in vitro killing of GBS [13] . In brief, a 75-mL volume of human polymorphonuclear leukocytes (PMNL) (1 £ 10 6 cells) was mixed with GBS strain 7357B (1:2 £ 10 5 cfu), 12.5 mL normal human serum as a complement source, and 12.5 mL human serum to be tested. Viable bacterial cells were counted (1 February) at time 0 and after 60 min of end-over-end incubation at 37 C. Results were reported as "log kill," which is the log of the difference between the number of cells counted at time 0 and at 60 min. Control assays were performed without PMNL or without complement. Additional control assays contained rabbit or human type Ib polysaccharide-specific antiserum. In some assays, purified native b C protein, fragments of the b protein (see next paragraph), or purified type Ib polysaccharide were included at varying concentrations to measure inhibition of opsonophagocytosis.
Generation of protein fragments corresponding to major regions within the b C protein. Fragments of the b C protein gene were prepared by PCR amplification of desired regions with the following primers, which were designed on the basis of published sequences (figure 1) [14, 15] 
0 . Amplified products were sequenced on an automated sequencer (ABI PRISM 377 DNA Sequencer; PerkinElmer/Cetus) at the Beth Israel Deaconess Medical Center Molecular Medicine Unit (Boston). Primers were designed to contain restriction sites that enabled cloning of the PCR products directly or via pCR2.1 into pTRCHisC (Invitrogen). Protein fragments then were expressed in Escherichia coli strain BLR (Novagen) as fusion proteins with a polyhistidine tag and were purified over a nickel-affinity spin column (CytoSignal), according to the manufacturer's instructions. In this way, fragments 2-7 were produced (figure 1).
Immunoblots. Immunoblotting was performed on purified b protein or on fragments of the b C protein by use of a modified dot-blot technique [6] . Approximately 0.3 mg of purified b C protein or b protein fragments were applied to a nitrocellulose membrane and incubated with rabbit antiserum raised to purified b C protein, monoclonal antibody 3E7, human serum, or human myeloma IgA (ICN Pharmaceuticals/Cappell). Human serum samples were selected if they had a b-specific IgG concentration >1.8 mg/ mL. The limiting dilution of reactivity with the whole b C protein was determined for each of the human serum samples tested and for the rabbit b-specific antiserum. In subsequent dot-blots, those fragments that showed reactivity with serum at the respective limiting dilutions were considered to be immunodominant.
Results
Purification of b C protein. b C protein extracted from strain 7357B appeared as a dominant 130-kD band on Coomassiestained SDS-PAGE and Western blot that used monoclonal antibody 3E7. Antiserum specific to other known GBS proteins, including the a C proteins Alp2 and Alp3, did not react with the preparation on Western blot. Type Ib polysaccharide was present in the b C protein preparation at a concentration of 0.26% by weight, according to ELISA inhibition (data not shown). The b C protein yield from a 1-L culture was 16.6 mg. The SDS content was 7% by weight.
Development of a b-specific ELISA. A quantitative ELISA was developed to determine levels of b C protein-specific IgG Figure 1 . Fragments of b C protein produced to correspond to major regions defined by Jerlstrom et al. [15] . A, IgA binding region A; B, IgA binding region B; M, membrane-associated region; S, signal sequence; Wn, non-repeat-containing wall-spanning region; Wr, repeat-containing wall-spanning region. Nos. in parentheses correspond to amino acid numbers of the b C protein, as defined by Jerlstrom et al. [15] . Arrows depict primers listed in Materials and Methods. levels in human serum samples. When checkerboard assays with a moderately high-titered b human reference serum were used, the optimal coating concentration of the b C protein was determined to be 1.25 mg/mL, and the optimal secondary antibody (goat anti-human IgG) dilution was 1:3000. The assay is highly specific, as was demonstrated by the ability to inhibit 94.3% of the ELISA activity with the addition of purified b C protein as an inhibiting antigen (figure 2). The addition of human serum albumin did not inhibit antibody binding to the b C protein in this assay. There was a linear relationship between absorbance readings and concentration of b-specific IgG, in reference serum, to a b-specific IgG concentration of 0.15 ng/mL; therefore, the limit of detection was 15 ng/mL, with an initial serum concentration of 1:100. The geometric mean concentration^SD of the internal control from 14 ELISA plates was 1:85^0:27 mg/mL (range, 1.5-2.28 mg/mL).
Lack of interference by serum IgA. Because the b C protein nonspecifically binds IgA [9, 16, 17] , we investigated the possibility that IgA present in human serum might interfere with the IgG ELISA, by reducing, for example, the number of binding sites available on the b-coated plates. Inhibition ELISA that used human IgA as the inhibiting antigen demonstrated no inhibition at a concentration as high as 105 mg/mL (figure 2). Removal of IgA from the b human reference serum using a jacalin column did not significantly alter the results of the IgG ELISA ( figure  3 ). These experiments indicate that the IgA binding property of the b protein does not affect the detection of b-specific IgG antibodies in this system.
Measurement of b-specific IgG in maternal serum. b-Specific IgG was measured in 5 case and 13 control serum samples (figure 4). For the 5 case samples, the b-specific IgG concentrations were 0.49-7.07 mg/mL, with a geometricmean concentration of 1.51 mg/mL. For the 13 control samples, the levels were 0.17-34.2 mg/mL, with a geometric mean concentration of 1.88 mg/mL. Levels of b-specific antibody were .2 mg/mL in 2 case serum samples (3.18 and 7.07 mg/mL, respectively).
Lack of opsonic activity of naturally acquired b-specific antibody. The b human reference serum was used in an opsono- (1 February) phagocytic assay to assess the functional capacity of naturally acquired antibodies to the b C protein. The b human reference serum, at a final dilution of 1:10, produced 1.06 log kill; no effect was seen with more-dilute concentrations of this serum. The addition of purified type Ib polysaccharide abolished opsonic activity entirely, which indicates that the opsonic activity was due to type Ib polysaccharide-specific antibody and not to bspecific IgG. Opsonophagocytic assays were performed with use of case and control serum samples in which the b-specific antibody level was >0.8 mg/mL. The final serum dilution in all assays using case or control serum samples was 1:10. One of 11 control serum samples produced 0.6 log kill, 2 others produced between 0.3 and 0.4 log kill, and the remainder produced >0.2 log kill. One of 4 case serum samples produced 0.35 log kill; 3 other case serum samples demonstrated no opsonic activity. In contrast, b C protein-induced rabbit b-specific antibody at a final dilution of 1:500 produced 1 log kill at 60 min; this was not affected by addition of polysaccharide.
Mapping of opsonic activity to a fragment of the b C protein. To investigate the difference in protection afforded by vaccineinduced b-specific rabbit antiserum and naturally acquired bspecific human IgG, mapping of antigenic domains within the b C protein was undertaken. Protein fragments corresponding to major regions within the b C protein were produced (figure 1), blotted onto nitrocellulose membranes, and probed with rabbit b-specific polyclonal antiserum or with human antiserum from 5 healthy adult volunteers, 2 mothers of infants with early-onset neonatal GBS disease (case patients), or 7 mothers of healthy neonates (control subjects). Human serum samples were selected if they had a b-specific IgG concentration >1.8 mg/ mL. In each group of serum samples, fragment 3, an N-terminal region that contained the IgA binding locus, was the predominant fragment recognized by serum used at the highest dilutions at which the whole b C protein was recognized ( figure 1 ). This fragment includes fragment 5, which also is recognized by most types of serum. Thus, these data do not reveal a major difference, in the regions recognized, either between vaccineinduced rabbit b-specific IgG and naturally acquired human b-specific IgG or between human case and control IgG.
To identify regions within the b C protein that contain opsonic epitopes, opsonic inhibition experiments were performed. Purified b C protein and fragment 5 completely blocked opsonic activity of rabbit b-specific antiserum at final antibody concentrations of >0.75 mg/mL.
Human myeloma IgA reacted only with fragments 3, 4, and 6, confirming observations elsewhere that region A contains the primary IgA binding region of the b C protein [16, 18] (data not shown). Monoclonal antibody 3E7 reacted with fragments 3 and 5, compatible with a binding site in the B or Wr region.
Discussion
We describe a quantitative ELISA for the measurement of human IgG specific for the b C protein, a potential candidate for the protein carrier of a GBS conjugate vaccine. Quantitative measurement of antibodies to GBS protein antigens has not been reported elsewhere and should be useful for evaluating the role of naturally acquired and vaccine-induced b-specific antibodies in immunity to GBS disease. The assay reported here is sensitive, specific, and highly reproducible. Although the b C protein binds to human IgA, no effect of IgA1 binding on the detection of b-specific IgG was observed.
Using this assay, we evaluated b-specific IgG concentrations in serum samples from mothers whose neonates developed earlyonset type Ib GBS disease and from type Ib GBS-colonized mothers whose neonates remained healthy. The 2 groups had similar levels of b-specific serum IgG. This finding contrasts to previous work that has demonstrated an association between high levels of human maternal antibody specific for GBS capsular polysaccharides and protection from early-onset GBS disease [2, 19] and to experiments in animals in which vaccine-induced bspecific antibody is functional in vitro and protective in experimental models [4] . In humans, the minimal protective level of maternal type Ib capsular polysaccharide-specific IgG is not known, but concentrations .0.2 mg/mL have been associated with protection from lethal challenge in experimental animals [20] and were not seen in neonates with invasive type Ib GBS disease [19] . In the current study, serum samples from 2 patients whose infants developed GBS disease demonstrated b-specific antibody levels .2 mg/mL. Furthermore, serum samples that con- tained moderately high levels of naturally acquired b-specific IgG did not promote opsonic killing in vitro. No major difference in epitope specificity was found to explain a difference in protection afforded by b-specific antibodies among different groups.
Studies by others have supported the hypothesis that IgA binding may contribute to a lack of opsonization by b-specific antibodies. In studies of type II GBS disease, Payne et al. [21] suggested that the presence of both the trypsin-sensitive and trypsin-resistant components of the C protein-namely, the b and a C proteins-contributed to the resistance to opsonophagocytosis in the presence of human serum. Additional studies have shown that jacalin treatment of serum that contains moderately high levels of type II capsular polysaccharidespecific antibodies leads to more-efficient opsonization of a type II/C protein GBS strain by mononuclear cells than was observed with nontreated serum, although killing was not increased, which suggests that the presence of IgA1 may interfere with opsonization by antibody to the type Ib capsular polysaccharide [22] . Moreover, nonimmune IgA binding has been reported to interfere with efficient IgG-mediated opsonization via diverse mechanisms in a number of different organisms, including group A streptococci [23, 24] , Neisseria meningitidis [25, 26] , N. gonorrhoeae [27] , and Brucella abortus [28] . In our study, human IgA did not interfere with the measurement by ELISA of bspecific IgG. Additional investigation may elucidate an effect of IgA binding on b C protein-specific opsonophagocytosis of type Ib GBS and will be important in the consideration of this antigen as a vaccine component.
The b C protein has been an attractive candidate for use in a conjugate GBS vaccine because, in animals used for experimental models, it acts both as an effective carrier protein for GBS polysaccharide and as a protective immunogen [4] . In the present study, we were unable to show a relationship between naturally acquired human antibody to the b C protein and protection from neonatal disease, but vaccine-induced antibodies may act differently. Studies of Pseudomonas aeruginosa lipopolysaccharide, for example, indicate that vaccine-induced antibodies have a higher affinity for the antigen than do naturally occurring antibodies [29] and that quantitative and qualitative changes in naturally acquired antibodies may occur over time [30] . Whether similar phenomena relate to b C protein-specific antibodies are not known. Additional studies are needed to more fully define the potential of the b C protein in GBS vaccines.
